Free Trial
→ INSANE DRONE FOOTAGE (From Paradigm Press) (Ad)tc pixel
NASDAQ:AGEN

Agenus Q3 2026 Earnings Date & Estimates

Agenus logo
$6.71 -0.24 (-3.45%)
As of 11:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Agenus is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for November 3, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Agenus in Q3 2026

Agenus is expected to post earnings of $0.02 per share on revenue of $28.20 million. In the same quarter a year earlier Agenus reported $1.94 per share on revenue of $30.24 million. Agenus last reported on August 7, 2026, posting -$0.01 per share and missing the $0.05 consensus estimate. Agenus has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.02
Expected Revenue
$28.20 million
Prior-Year EPS
$1.94
Prior-Year Revenue
$30.24 million
Expected EPS Growth
-99.0%
Expected Revenue Growth
-6.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.01 (Missed by -$0.06)
Last Quarter Revenue
$34.52 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Agenus Q3 2026 Earnings FAQ

Agenus (NASDAQ:AGEN) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Agenus' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Agenus to post earnings of $0.02 per share for Q3 2026.

The consensus revenue estimate for Agenus is $28.20 million for Q3 2026.

Agenus Earnings Headlines

Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/agenus-participate-chardan-10th-annual-192300804.html
Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference
October 9, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261009464799/en/agenus-to-participate-in-chardan%e2%80%99s-10th-annual-healthcare-investor-conference/
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
October 14 at 1:00 AM  |  Porter & Company (Ad)
Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/agenus-gets-armenia-approval-botensilimab-120145302.html
Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
October 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261008022628/en/Armenia-Grants-First-Marketing-Authorizations-for-Agenus%E2%80%99-BOTBAL-in-Previously-Treated-MSS-Metastatic-Colorectal-Cancer/
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
October 8, 2026  |  financialpost.comF
See More Agenus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Agenus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Agenus and other key companies, straight to your email.

About Agenus

Agenus (NASDAQ:AGEN) (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with an emphasis on therapies that may be used alone or in combination.

Agenus’ pipeline includes botensilimab, an investigational Fc-enhanced CTLA-4 antibody, and balstilimab, an investigational PD-1 inhibitor. The company has studied these therapies in combination across several solid-tumor indications, including colorectal cancer and other advanced cancers. Agenus also develops additional immune checkpoint inhibitors, bispecific antibodies and cancer vaccine technologies intended to address different aspects of the tumor microenvironment.

The company was founded in 1994 as Antigenics and adopted the Agenus name in 2011. Headquartered in Lexington, Massachusetts, Agenus conducts research and clinical development activities through operations and collaborations supporting programs in the United States and internationally. Garo H. Armen, Ph.D., is the company’s co-founder and chief executive officer.

View Agenus Profile
Earnings Tools